Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Coronary Intravascular Lithotripsy (IVL): Clinical Performance and Safety
Coronary intravascular lithotripsy (IVL) is an established plaque-modification technique designed to facilitate optimal stent expansion in moderately to severely calcified coronary lesions. By delivering localized acoustic pressure waves through a low-pressure balloon system, IVL induces controlled microfractures in both superficial and deep calcium, improving vessel compliance while minimizing vascular trauma.
Clinical evidence from the Disrupt CAD I–IV trials demonstrates a procedural success rate of approximately 92%, defined by successful stent delivery with residual stenosis below target thresholds and absence of in-hospital major adverse cardiac events. In these studies, residual stenosis <50% was achieved in approximately 95% of treated lesions, reflecting effective calcium modification and favorable acute luminal gain.
Importantly, IVL is associated with a low incidence of serious complications, including a coronary perforation rate below 1%, which is substantially lower than that reported with some atherectomy-based strategies. This safety profile, combined with technical simplicity and a short learning curve, supports IVL as a valuable option for contemporary percutaneous coronary intervention in calcified coronary artery disease.”
Title: Shocking the Rock With Coronary Intravascular Lithotripsy in Contemporary Practice
Authors: Debabrata Dash, Anna Emily Bortnic
Read the Full Article on American College of Cardiology
Stay updated with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis